## **Ulf Elbelt**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5989597/publications.pdf

Version: 2024-02-01

35	1,572	22	38
papers	citations	h-index	g-index
38	38	38	2535
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – Correlation with body mass index. Peptides, 2013, 39, 125-130.	2.4	341
2	Irisin as a muscle-derived hormone stimulating thermogenesis – A critical update. Peptides, 2014, 54, 89-100.	2.4	126
3	Diagnosis of Primary Hypophysitis in Germany. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3841-3849.	3.6	98
4	Treatment of Primary Hypophysitis in Germany. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3460-3469.	3.6	88
5	Molecular and Clinical Evidence for an <i>ARMC5</i> Tumor Syndrome: Concurrent Inactivating Germline and Somatic Mutations Are Associated With Both Primary Macronodular Adrenal Hyperplasia and Meningioma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E119-E128.	3.6	85
6	Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Frontiers in Neuroscience, 2015, 9, 199.	2.8	79
7	Ghrelin and NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects. Histochemistry and Cell Biology, 2013, 139, 909-918.	1.7	68
8	NUCB2/nesfatin-1 is associated with elevated scores of anxiety in female obese patients. Psychoneuroendocrinology, 2013, 38, 2502-2510.	2.7	57
9	The ghrelin activating enzyme ghrelin-O-acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass index. Peptides, 2013, 43, 13-19.	2.4	51
10	Sex-specific regulation of NUCB2/nesfatin-1: Differential implication in anxiety in obese men and women. Psychoneuroendocrinology, 2015, 60, 130-137.	2.7	50
11	NUCB2/nesfatin-1 Is Associated with Elevated Levels of Anxiety in Anorexia Nervosa. PLoS ONE, 2015, 10, e0132058.	2.5	45
12	Differences of energy expenditure and physical activity patterns in subjects with various degrees of obesity. Clinical Nutrition, 2010, 29, 766-772.	5.0	44
13	Irisin Levels are Not Affected by Physical Activity in Patients with Anorexia Nervosa. Frontiers in Endocrinology, 2014, 4, 202.	3.5	40
14	Plasma kisspeptin and ghrelin levels are independently correlated with physical activity in patients with anorexia nervosa. Appetite, 2017, 108, 141-150.	3.7	38
15	Determinants of Weight Loss following Laparoscopic Sleeve Gastrectomy: The Role of Psychological Burden, Coping Style, and Motivation to Undergo Surgery. Journal of Obesity, 2015, 2015, 1-10.	2.7	34
16	Phoenixin is negatively associated with anxiety in obese men. Peptides, 2017, 88, 32-36.	2.4	34
17	Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas—A German Survey. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e660-e675.	3.6	34
18	Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. European Journal of Endocrinology, 2009, 160, 919-924.	3.7	31

#	Article	IF	CITATIONS
19	Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype. European Journal of Endocrinology, 2016, 175, 421-431.	3.7	31
20	Irisin. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 541-547.	2.5	29
21	Determinants of Successful Weight Loss After Using a Commercial Web-Based Weight Reduction Program for Six Months: Cohort Study. Journal of Medical Internet Research, 2013, 15, e219.	4.3	28
22	Intraoperative indocyanine green videoangiography for identification of pituitary adenomas using a microscopic transsphenoidal approach. Pituitary, 2015, 18, 613-620.	2.9	23
23	Alterations of circulating NUCB2/nesfatin-1 during short term therapeutic improvement of anxiety in obese inpatients. Psychoneuroendocrinology, 2017, 79, 107-115.	2.7	20
24	Abdominal fat distribution differently affects muscle strength of the upper and lower extremities in women. European Journal of Clinical Nutrition, 2017, 71, 372-376.	2.9	17
25	Leptin and Physical Activity in Adult Patients with Anorexia Nervosa: Failure to Demonstrate a Simple Linear Association. Nutrients, 2017, 9, 1210.	4.1	14
26	Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150082.	0.5	13
27	The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. Journal of Clinical Medicine, 2018, 7, 289.	2.4	11
28	Surgically and Conservatively Treated Obese Patients Differ in Psychological Factors, Regardless of Body Mass Index or Obesity-Related Co-Morbidities: A Comparison between Groups and an Analysis of Predictors. PLoS ONE, 2015, 10, e0117460.	2.5	9
29	Evaluation of a Portable Armband Device to Assess Resting Energy Expenditure in Patients With Anorexia Nervosa. Nutrition in Clinical Practice, 2016, 31, 362-367.	2.4	6
30	Essential Polyunsaturated Fatty Acids in Blood from Patients with and without Catheter-Proven Coronary Artery Disease. International Journal of Molecular Sciences, 2022, 23, 766.	4.1	6
31	Associations of physical activity with depressiveness and coping in subjects with high-grade obesity aiming at bariatric surgery: a cross-sectional study. BioPsychoSocial Medicine, 2015, 9, 16.	2.1	5
32	Association of Interleukin-1 Beta and Interleukin-1 Receptor Antagonist Gene Polymorphisms and Plasma Levels with Diabetic Nephropathy. BioMed Research International, 2022, 2022, 1-7.	1.9	5
33	Self-Directed Weight Loss Strategies: Energy Expenditure Due to Physical Activity Is Not Increased to Achieve Intended Weight Loss. Nutrients, 2015, 7, 5868-5888.	4.1	4
34	NUCB2/nesfatin-1 is associated with severity of eating disorder symptoms in female patients with obesity. Psychoneuroendocrinology, 2022, 143, 105842.	2.7	2
35	Estimating Resting Energy Expenditure With a Portable Armband Device in an Ambulatory Setting. Nutrition in Clinical Practice, 2012, 27, 825-831.	2.4	1